The University of Cambridge and Elan have launched The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University of Cambridge, England. The Cambridge-Elan Centre will provide an interdisciplinary environment uniquely positioned for delivering translational research focused on innovative therapies for Alzheimer's and Parkinson's diseases. This ten-year agreement paves the way for a long-term collaboration between Elan and the University of Cambridge.
The goal of the Cambridge-Elan Centre is to discover novel compounds capable of altering the behavior of proteins associated with neurodegenerative disorders that can be developed into new treatments. The Centre will bring together Elan's two decades of experience in Alzheimer's research and its depth in biology and model systems with the University of Cambridge's pioneering contributions in the development of biophysical approaches to study the molecular basis of protein misfolding and aggregation, and their links to disease.
The Cambridge-Elan Centre will enable investigators across the two organizations to explore novel approaches to improve the understanding of biophysical and biochemical aspects of protein folding and misfolding, and to explore unique approaches to modulate these processes in an effort to discover new therapeutics.
"Protein folding, misfolding and turnover are central to neurological disease and will be the basis for further scientific and therapeutic advancements. Our relationship with Cambridge will enable us to address the interconnecting biology and biophysics of protein misfolding in multiple disease areas simultaneously and in a timely way for the ultimate benefit of patients," Ted Yednock, executive vice president and head of discovery and translation for Elan.
"I believe that we are creating a Centre that will become globally recognized for innovation. Our collective expertise, proven ability to collaborate, and open innovation model provide an exciting basis for the future. The new Centre will bring together the skills of scientists working in an academic institution and in a biotechnology company to develop new and more effective therapies for some of the most devastating and increasingly common human diseases," said Christopher Dobson, professor at the University of Cambridge.